India’s Biotech Renaissance: Dr. Jogin Desai Forecasts Breakthrough Therapies Every Two Years
India is transitioning from a global manufacturing hub to a leader in deeptech innovation. In this featured interview, Dr. Jogin Desai, CEO of Eyestem, explores how a compressed therapy timeline, the ₹10,000 crore Biopharma SHAKTI programme, and a focus on “reversing” rather than just “slowing” diseases are positioning India to deliver life-changing medical solutions to the world at a fraction of the traditional cost.
